within Pharmacolibrary.Drugs.N_NervousSystem.N05B_Anxiolytics.N05BA14_Pinazepam;

model Pinazepam
  extends Pharmacolibrary.Drugs.ATC.N.N05BA14;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>N05BA14</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Pinazepam is a benzodiazepine derivative primarily used for its anxiolytic and sedative effects. It is indicated for the short-term treatment of anxiety and related disorders. Pinazepam is not widely approved or marketed today in most countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are not directly reported in the existing literature for healthy adult subjects; thus, the following are estimates based on known properties of oral benzodiazepines and available indirect data.</p><h4>References</h4><ol><li><p>Pacifici, GM, et al., &amp; Gomeni, R (1983). Pharmacokinetics of pinazepam in healthy volunteers. <i>International journal of clinical pharmacology research</i> 3(5) 331–337. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6147314/&quot;>https://pubmed.ncbi.nlm.nih.gov/6147314</a></p></li><li><p>Pacifici, GM, et al., &amp; Placidi, GF (1982). Disposition, distribution, and liver first-pass effect of pinazepam in the rat. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 10(2) 180–182. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6124406/&quot;>https://pubmed.ncbi.nlm.nih.gov/6124406</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Pinazepam;
